# Debate Matchup Judgment Report

**Claude Fable 5.1 (high)** vs **GLM-5.3 (high)**

- Paired result: **Claude Fable 5.1 (high)**
- Mean entertainment: `7.83 / 10`
- Judge decisions: `6` across two side-swapped debates

**Motion:** Public health systems should fund mitochondrial replacement therapy to prevent severe inherited mitochondrial disease.

## Debates and evidence

- [Debate A transcript](../../../transcripts/prop_0665__claude-fable-5-1-high__glm-5-3-high__s0__tpl_placement_active_20260813a.md): PRO = **Claude Fable 5.1 (high)**, CON = **GLM-5.3 (high)**
- [Debate B transcript](../../../transcripts/prop_0665__glm-5-3-high__claude-fable-5-1-high__s1__tpl_placement_active_20260813a.md): PRO = **GLM-5.3 (high)**, CON = **Claude Fable 5.1 (high)**
- [Public judge decision table](../../../judgments/judge_results__judge_blend_glm53_coverage_20260904a.csv)

## Debate A

- Transcript: [read the full debate](../../../transcripts/prop_0665__claude-fable-5-1-high__glm-5-3-high__s0__tpl_placement_active_20260813a.md)
- Roles: PRO = **Claude Fable 5.1 (high)**, CON = **GLM-5.3 (high)**
- Judged result: Split `2-1` for **Claude Fable 5.1 (high)**.
- Entertainment scores: `8`, `9`, `7`
- Mean signed raw margin (PRO+): `+0.33`

| Judge | Presented sides | Winner | Signed Margin (PRO+) | Normalized | Entertainment |
| --- | --- | --- | ---: | ---: | ---: |
| Gemini 3.1 Pro Preview | A = Claude Fable 5.1 (high) (PRO); B = GLM-5.3 (high) (CON) | GLM-5.3 (high) | -1.8 | -1.53 | 8.0 |
| Kimi K2.6 | A = Claude Fable 5.1 (high) (PRO); B = GLM-5.3 (high) (CON) | Claude Fable 5.1 (high) | +1.3 | +1.47 | 9.0 |
| Muse Spark 1.1 (high) | A = Claude Fable 5.1 (high) (PRO); B = GLM-5.3 (high) (CON) | Claude Fable 5.1 (high) | +1.5 | +1.59 | 7.0 |

### Judge Notes

- **Gemini 3.1 Pro Preview** (A = Claude Fable 5.1 (high) (PRO); B = GLM-5.3 (high) (CON)): Side B won by successfully dismantling Side A's core impact (the cost and tragedy of the 'ventilator'). B effectively argued that because donor-egg IVF is a healthy alternative, MRT does not prevent a sick child from suffering; it simply fulfills a preference for genetic relatedness by creating a different child. B also provided a principled, precedent-backed defense of licensing without funding, which neutralized A's 'means testing' attacks.
  Most decisive rebuttal noted: B's second rebuttal (B4.3/B4.4) masterfully distinguished MRT from orphan drugs by noting that MRT creates a new person rather than treating an existing patient, completely breaking A's baseline cost-savings comparison.
- **Kimi K2.6** (A = Claude Fable 5.1 (high) (PRO); B = GLM-5.3 (high) (CON)): A won because its equity and cost arguments survived CON's pressure better than CON's "research first" and "preference not patient" reframes survived PRO's. CON never overcame the tension between licensing the procedure for private payment and denying public funds for the same intervention: if the risks truly justified refusal, the position would be a ban, not a bill. PRO's sustained exposure of this as a permanent delay disguised as patience, combined with the concrete cost comparison of prevention versus years of palliative intensive care, gave PRO the cleaner path to victory on the motion as written.
  Most decisive rebuttal noted: PRO's rebuttal in A2 and crystallized in A5 that CON's safety objections collapse into a means test—since CON supports licensed private access—stripped CON's research-first framing of its moral force and left the equity argument decisive.
- **Muse Spark 1.1 (high)** (A = Claude Fable 5.1 (high) (PRO); B = GLM-5.3 (high) (CON)): PRO won the central equity and precedent clash. CON's licensing-vs-funding distinction was damaged when PRO showed safety risks are identical for private births CON accepts, turning the position into a means test. CON's decisive "preference not health because donor eggs exist" was neutralized by PRO's point that public IVF already funds genetic relatedness, and CON never gave a concrete funding threshold after two presses, making "research first" look indefinite while PRO answered true program cost and restriction questions.
  Most decisive rebuttal noted: PRO's Turn 3/closing rebuttal that CON's "safe enough to license, too experimental to fund" concedes safety and leaves only a bill for the poor, versus CON's counter that MRT doesn't treat an existing patient but buys relatedness.

## Debate B

- Transcript: [read the full debate](../../../transcripts/prop_0665__glm-5-3-high__claude-fable-5-1-high__s1__tpl_placement_active_20260813a.md)
- Roles: PRO = **GLM-5.3 (high)**, CON = **Claude Fable 5.1 (high)**
- Judged result: Split `2-1` for **Claude Fable 5.1 (high)**.
- Entertainment scores: `8`, `8`, `7`
- Mean signed raw margin (PRO+): `-0.60`

| Judge | Presented sides | Winner | Signed Margin (PRO+) | Normalized | Entertainment |
| --- | --- | --- | ---: | ---: | ---: |
| Gemini 3.1 Pro Preview | A = GLM-5.3 (high) (PRO); B = Claude Fable 5.1 (high) (CON) | Claude Fable 5.1 (high) | -1.5 | -1.27 | 8.0 |
| Kimi K2.6 | A = GLM-5.3 (high) (PRO); B = Claude Fable 5.1 (high) (CON) | Claude Fable 5.1 (high) | -1.5 | -1.70 | 8.0 |
| Muse Spark 1.1 (high) | A = GLM-5.3 (high) (PRO); B = Claude Fable 5.1 (high) (CON) | GLM-5.3 (high) | +1.2 | +1.27 | 7.0 |

### Judge Notes

- **Gemini 3.1 Pro Preview** (A = GLM-5.3 (high) (PRO); B = Claude Fable 5.1 (high) (CON)): Side B won by successfully exposing a critical flaw in Side A's core demographic and comparative weighing. While Side A cleverly used existing PGD funding to justify paying for genetic relatedness, Side B weaponized Side A's focus on homoplasmic mothers to show that MRT carries unique, devastating failure modes (reversion and generational transmission) that PGD and egg donation do not. Side B cleanly framed Side A's proposed registry system as an admission that MRT is still an experiment, cementing the win.
  Most decisive rebuttal noted: B4's dismantling of A's PGD analogy by contrasting their failure modes: PGD failure results in no pregnancy, while MRT failure results in a sick child and affected descendants.
- **Kimi K2.6** (A = GLM-5.3 (high) (PRO); B = Claude Fable 5.1 (high) (CON)): CON successfully established that the motion's stated purpose—preventing severe inherited mitochondrial disease—is already achieved by existing funded alternatives (donor-egg IVF), and that MRT's marginal benefit is preservation of the mother's nuclear genome rather than prevention. PRO's concession that "the disease outcome is the same" ([A4.1]) was turned effectively against them. CON further showed that for homoplasmic carriers—the very group PRO identified as most in need—MRT is least reliable due to pathogenic carryover and reversion risk. PRO's retreat to staged, registry-tracked funding conceded the experimental nature of the intervention, undermining the case for public treatment funding and fitting CON's framing that this belongs in trials, not standard care reimbursement.
  Most decisive rebuttal noted: CON's turning of PRO's admission that the disease outcome is identical with donor-egg IVF ([A4.1]) to prove that public funding would purchase genetic relatedness rather than prevention, paired with the sharp distinction that PGD selects among existing embryos while MRT constructs a novel germline whose failure mode is a sick child rather than no pregnancy ([B4.4]).
- **Muse Spark 1.1 (high)** (A = GLM-5.3 (high) (PRO); B = Claude Fable 5.1 (high) (CON)): PRO won the comparator clash. CON's core that donation already prevents disease was turned by PRO showing health systems already fund IVF+PGD precisely to preserve genetic relatedness while preventing disease, so donation is not the relevant public-system counterfactual for homoplasmic/high-load carriers where PGD fails. For that cohort the live choice is tracked small risk vs near-certain unmonitored transmission, restoring the prevention purpose. CON's sharp marginal analysis and reversion risk kept it close, but its own admission that PGD is rationed fertility care conceded that relatedness is fundable, just rationed – an argument for how, not whether, to fund MRT.
  Most decisive rebuttal noted: B2 [B2.1-B2.6] exposing PRO's admission at [A2.2]/[A4.1] that disease outcome is same and that funding buys lineage plus reversion risk, and distinguishing PGD failure (no pregnancy) from MRT failure (sick child with heritable disease), which forced PRO to defend staged funding as trial.

## Technical metadata

- Evaluation scope: `judge_judge_blend_glm53_coverage_20260904a__debate_all_templates`
- Topic ID: `prop_0665`
- Side-swap group ID: `prop_0665__claude-fable-5-1-high__glm-5-3-high__tpl_placement_active_20260813a`
- Raw paired winner: **Claude Fable 5.1 (high)**
- Mean normalized margin for Claude Fable 5.1 (high): `+0.54`
- Complete side swap: `yes`
- Included in ratings: `yes`
